- Home
- BIIB vs STX Comparison
BIIB vs STX Comparison
Compare BIIB & STX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- STX
- Stock Information
- Founded
- BIIB 1978
- STX 1978
- Country
- BIIB United States
- STX Singapore
- Employees
- BIIB N/A
- STX N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- STX Electronic Components
- Sector
- BIIB Health Care
- STX Technology
- Exchange
- BIIB Nasdaq
- STX Nasdaq
- Market Cap
- BIIB 18.7B
- STX 33.0B
- IPO Year
- BIIB 1991
- STX 2002
- Fundamental
- Price
- BIIB $144.87
- STX $213.36
- Analyst Decision
- BIIB Buy
- STX Buy
- Analyst Count
- BIIB 27
- STX 20
- Target Price
- BIIB $188.09
- STX $161.95
- AVG Volume (30 Days)
- BIIB 1.5M
- STX 3.5M
- Earning Date
- BIIB 10-29-2025
- STX 10-21-2025
- Dividend Yield
- BIIB N/A
- STX 1.35%
- EPS Growth
- BIIB 31.67
- STX 328.48
- EPS
- BIIB 10.45
- STX 6.77
- Revenue
- BIIB $9,997,000,000.00
- STX $9,097,000,000.00
- Revenue This Year
- BIIB $2.00
- STX $16.54
- Revenue Next Year
- BIIB N/A
- STX $9.96
- P/E Ratio
- BIIB $13.83
- STX $31.56
- Revenue Growth
- BIIB 3.36
- STX 38.86
- 52 Week Low
- BIIB $110.04
- STX $63.19
- 52 Week High
- BIIB $204.18
- STX $215.20
- Technical
- Relative Strength Index (RSI)
- BIIB 60.19
- STX 86.59
- Support Level
- BIIB $141.12
- STX $163.86
- Resistance Level
- BIIB $147.23
- STX $215.20
- Average True Range (ATR)
- BIIB 4.65
- STX 6.73
- MACD
- BIIB 0.23
- STX 2.97
- Stochastic Oscillator
- BIIB 71.16
- STX 96.42
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About STX Seagate Technology Holdings PLC (Ireland)
Seagate Technology is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital; they are both vertically integrated.